Novartis, a Swiss multinational pharmaceutical company, completed the acquisition of Gyroscope Therapeutics, an ocular gene therapy company, from Syncona, a closed-ended investment healthcare company, for $1.5bn. "With our own pioneering research in ocular gene therapies and our experience gained from bringing Luxturna to inherited retinal dystrophy patients outside of the US, Novartis has a well-established expertise in ocular gene therapies that will position us well to continue developing this promising one-time treatment. This acquisition is one more step forward in our commitment to delivering innovation in ophthalmology to treat and prevent blindness worldwide," Marie-France Tschudin, Novartis President.